Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12324805 | 0.81 | DRD2 (0.57) | DRD2DRD4ALOX15PARP11HRH3 | |
| SCHEMBL13372830 | 0.75 | TAAR1 (0.80) | TAAR1ALOX15HTR1AADRA2AADRA2B | |
| SCHEMBL2347299 | 0.74 | TAAR1 (0.46) | TAAR1HTR1APARP11HRH3 | |
| SCHEMBL8870301 | 0.73 | PARP11 (0.63) | TAAR1DRD2DRD4PARP11ADRA2A | |
| SCHEMBL31414967 | 0.72 | TAAR1 (0.75) | TAAR1ALOX15HTR1AADRA2AADRA2B | |
| SCHEMBL11295655 | 0.71 | TAAR1 (0.58) | TAAR1ALOX15HTR1AADRA2AADRA2B | |
| SCHEMBL9090100 | 0.71 | NISCH (0.46) | DRD2DRD4HRH3JAK2JAK3 | |
| SCHEMBL12736108 | 0.71 | DRD2 (0.58) | DRD2DRD4ALOX15PARP11HRH3 | |
| SCHEMBL12324832 | 0.71 | MAPT (0.53) | DRD2DRD4ALOX15PARP11HRH3 | |
| SCHEMBL13594078 | 0.71 | DRD2 (0.53) | DRD2DRD4ALOX15PARP11HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2344491-A2 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS | Schering Corporation (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042477-A1 | BENZODIOXAN ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010033495-A2 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-5538973-A | ANTIHISTAMINE, THROMBOXANE A2 ANTAGONIST | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0597112-A1 | NOVEL IMIDAZOLE DERIVATIVE, PHARMACEUTICAL USE THEREOF, AND INTERMEDIATE THEREFOR | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028940-A1 | FUNCTIONALLY SELECTIVE AZANITRILE ALPHA-2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | TAAR1 51/4885DRD2 269/4885DRD4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.